Related Experiment Video
Updated: May 3, 2026
Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE
Published on: April 21, 2019
Cost-effectiveness of patch testing allergens within the same group: A computational approach to optimize
Ning C McKenzie1, Matthew R Buras2, James A Yiannias3
1Mayo Clinic Alix School of Medicine, Scottsdale, Arizona.
Background:
Patch testing for multiple cross-reactive allergens for allergic contact dermatitis (ACD) may not be necessary because of copositivity.
Objectives:
We evaluated the formaldehyde group allergens to determine the optimal, most cost-effective allergens to test.
Methods:
A retrospective analysis of Mayo Clinic (1997-2022) examined the well-established copositive formaldehyde group: formaldehyde, quaternium 15, hexahydro-1,3,5-tris(2-hydroxyethyl)triazine, diazolidinyl urea, imidazolidinyl urea, toluenesulphonamide formaldehyde resin, DMDM hydantoin, and ethyleneurea melamine formaldehyde mix. Patch Optimization Platform identified which single formaldehyde-related allergen optimally captures patients with clinically relevant ACD. Next, Patch Optimization Platform determined the optimal additional 1, 2, 3, etc. allergens. Cost per patch test was $5.19 (Medicare 2022).
Results:
A total of 9832 patients were tested for all listed allergens, with 830 having positive patch test results. Patch Optimization Platform determined that quaternium 15 alone captures 53% of patients with ACD to the formaldehyde group; adding the optimal second allergen (formaldehyde 1%) captures 78%; the optimal 5 top allergens capture >94% of patients. The incremental cost per additional diagnosis increased up to 44-fold as the number of allergens tested increased.
Limitations:
Data are from a single institution, and the cost per test was fixed according to Medicare Part B in 2022.
Conclusions:
For diagnosing ACD, we recommend considering an optimized allergen selection algorithm.
